NCT06633341 is a EARLY_PHASE1 clinical trial of CD5 CAR T-cells in T-lymphoblastic Lymphoma, sponsored by Zhejiang University.

Who is sponsoring NCT06633341?

NCT06633341 is sponsored by Zhejiang University.

What drugs are being tested in NCT06633341?

Interventions in NCT06633341: CD5 CAR T-cells.

What condition does NCT06633341 study?

NCT06633341 studies T-lymphoblastic Lymphoma.

Is NCT06633341 still recruiting?

NCT06633341 is currently recruiting now. Last updated 9 October 2024.

Last reviewed 2024-10-09 · How we verify

NCT06633341

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

Recruiting now EARLY_PHASE1 Last updated 9 October 2024

What this trial tests

EARLY_PHASE1 trial testing CD5 CAR T-cells in T-lymphoblastic Lymphoma in 30 participants. Currently enrolling.

Timeline

20 October 2024

Primary endpoint
20 October 2027

20 October 2027

Quick facts

Lead sponsor	Zhejiang University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 October 2024
Primary completion	20 October 2027
Estimated completion	20 October 2027
Sites	1 location across China

Drugs / interventions tested

CD5 CAR T-cells — full drug profile →

Conditions studied

T-lymphoblastic Lymphoma — all drugs for T-lymphoblastic Lymphoma →

Sponsor

Zhejiang University

Who can join

Eligibility, any sex, with T-lymphoblastic Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.
Casan JML, Ong XJ, van der Weyden C, Yannakou CK, et al · · 2025 · cited 1× · PMID 41295262 · DOI 10.3390/jpm15110560

Verify or expand the search:

Other trials of CD5 CAR T-cells

Trials testing the same drug.

NCT06633354 — Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL · EARLY_PHASE1 · recruiting

Other recruiting trials for T-lymphoblastic Lymphoma

Currently open trials in the same condition.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT06376721 — Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT06136364 — CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06633341 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 9 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing